Centennial, Colo. — November 16, 2018 — AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, received U.S. patent 10,105,793, titled Enclosure for laser cutting of human tissue.

This patent encompasses AlloSource’s method of producing a closed system that allows a laser beam to pass through and etch allograft tissue, while maintaining a sterile barrier. The proprietary method expedites processing, maximizes the use of tissue, and allows utilization of a specialized laser technology in a clean room setting.

The process is used to create ProChondrix® CR, AlloSource’s fresh cryopreserved osteochondral allograft. ProChondrix CR helps deliver the necessary components for articular cartilage restoration. This next generation of cartilage restoration therapy provides living functional cells and other biological components necessary for replacement, repair and regeneration of damaged cartilage tissues.

“As an organization dedicated to honoring tissue donation, this patent is a great example of our commitment to innovation,” said Dr. Ross Wilkins, AlloSource Senior Medical Director. “Laser etching stimulates the cartilage regenerative system while the graft replaces the missing cartilage in superficial defects down to the bone level. The early clinical results are very encouraging.”


About AlloSource
AlloSource is dedicated to advancing the science and use of transplantable allogeneic cells and tissue through pioneering research in regenerative therapies. The organization offers life-saving and life-enhancing solutions in orthopedic, spine, burn and wound procedures to help restore patient health and mobility. As a world leader in cell-based products, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource’s products bridge the proven science of allografts with the advanced technology of cells. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org.